Gaucher Disease Insights

HealthSpotlight is now AllMyHealth

Advertise with us
Exciting News!
HealthSpotlight is now AllMyHealth
Wondering why we have a brand new look? We have exciting news - HealthSpotlight has merged with and rebranded as AllMyHealth.

Our shared commitment to supporting rare disease communities with trusted resources and advocacy remains as strong as ever - now under a unified name that reflects our patient-first values.

We collaborate with patient support groups to create advocacy materials and amplify community news and events.

Want to work with us? Find out more here

Top Stories

FDA Accepts BLA for PRGN-2012 Gene Therapy
PRGN-2012 targets a different condition, Recurrent Respiratory Papillomatosis. It aims to reduce surgeries by triggering an immune response against specific viruses, offering an alternative treatment approach similar to how other gene therapies might address Gaucher Disease by targeting underlying causes.
Read More →
Reena Sharma Discusses Future Plans for FLT201
Researchers are exploring how FLT201 can improve lives for people with Gaucher disease by reducing lifelong treatment burdens and addressing unmet needs like bone complications.
Read More →
Ide-Cel and Lenalidomide Maintenance in Myeloma
Studies focus on improving responses in multiple myeloma, not directly impacting Gaucher Disease. However, advancements in treatments like ide-cel and lenalidomide could inspire similar approaches for other conditions.
Read More →

Latest Research

In their study, Bender et al. (2025) explored the underlying mechanisms of inborn errors of metabolism (IEM) by examining the role of modifier pathways, which are influenced by genetic variations. They generated molecular signatures of IEM in relevant tissues using RNA sequencing and integrated these with multiomic data from healthy populations.

Specifically for Gaucher disease, the research reaffirmed the role of complement signaling in the disease's inflammatory processes. This finding was a result of comparing disease signatures with gene regulatory networks from non-IEM individuals. The approach taken by Bender et al. offers a new way to understand IEM pathophysiology and could lead to the identification of novel drug targets.

Community News

Gaucher Community AllianceGaucher Community AllianceFeb 24, 2025

Join us this week on Capitol Hill with EveryLife Foundation for Rare Diseases for Rare Disease Week! We can’t wait to meet other rare disease advocates and make our voices heard by many members of Congress and government officials. See you there!

Gaucher Community Alliance Post
National Gaucher FoundationNational Gaucher FoundationFeb 20, 2025

You may have read about promising early results of using Ambroxol as a Gaucher disease medication ... but what exactly is it?

National Gaucher FoundationNational Gaucher FoundationFeb 25, 2025

Dr. Robin A. Ely, Clinical/Science Advisor, Director of the National Gaucher Foundation (NGF) Global Diagnostic and Treatment Initiative, and NGF Co-Founder, recently presented at the WORLDSymposium Conference.

She shares her experience at the event and her work on behalf of NGF.

🔗 https://www.gaucherdisease.org/blog/worldsymposium-2025/

Upcoming Events

MAR
27
Taking Time Off Work Webinar Gaucher Community Alliance    Online

Click Here to Join Our Community

Join Our Waitlist